retatrutide ly3437943 triple agonist gip glp-1 glucagon peptide LY3437943 in healthy participants in
Description
Adipogen Life Sciences
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
The problem is what the studies actually show.
While our current treatments have shown significant therapeutic benefits, there still appear to be some patients who, despite aggressive therapy, good adherence, and inhaler technique, continue to have exacerbations
In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c6.5%
